A variety of pharmacological strategies have been described aiming to rescue hippocampal LTP induction and restore cognitive functions in obesity, including the following: catecholaminergic stimulation [149]; administration of Glucagon-like peptide-1 (GLP-1) agonists, such as exendin-4 [150], or the insulin sensitizer, metformin [151]; blocking IL-1 signaling with the IL-1 receptor antagonist (IL-1RA) [152]; and rescuing the E/I ratio with a mixture of memantine and allopregnanolone, which, respectively, block NMDARs and GABAA receptors. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.